Xeris Biopharma Holdings, Inc.(XERS)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #1,162 of 2,962 stocksTOP 50%
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
XERS Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Xeris Biopharma Holdings, Inc. (XERS), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores XERS at 56.5/100 on a 32-signal composite quality model, placing it at rank #1,162 of 2,962 stocks — the top half of the AI-ranked universe. XERS scores in the top quartile across earnings quality (91.5), revenue growth (90.9). Areas of concern include balance sheet strength (23.6) and revenue scale (31.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 19.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Xeris Biopharma Holdings, Inc. reports quarterly revenue of $92.1M, net income of $-31.1M. Top institutional holders of XERS by reported 13-F value include BlackRock, CAPSTONE INVESTMENT ADVISORS, D. E. Shaw, based on the most recent SEC filings. XERS trades on the Nasdaq exchange and files with the SEC under CIK 1867096. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate XERS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Xeris Biopharma Holdings, Inc. directly from SEC EDGAR. Xeris Biopharma Holdings, Inc.'s 13F Pro composite quality score has ranged between 30 and 61 since 2022, currently 56.5 — an improving long-term trajectory across 64 quarterly and live scoring snapshots.
Revenue
Q2 2026
$92.1M
Net Income
Q2 2026
$-31.1M
ROIC
Q2 2026
6.8%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+43.7% YoYNet Income
+101.0% YoYOperating Income
+174.0% YoYEPS (Diluted)
+100.0% YoYTotal Assets
+18.7% YoYTotal Debt
-10.9% YoYOp. Cash Flow
+177.4% YoYFree Cash Flow
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $291.8M +43.7% | $203.1M +23.9% | $163.9M +48.7% | $110.2M +122.3% | $49.6M +142.7% | $20.4M |
| Net Income | $554.0K +101.0% | $-54.8M +11.9% | $-62.3M +34.2% | $-94.7M +22.9% | $-122.7M -34.7% | $-91.1M |
| Operating Income | $24.9M +174.0% | $-33.6M +23.5% | $-44.0M +46.3% | $-81.9M +28.8% | $-115.2M -37.8% | $-83.5M |
| EPS (Diluted) | $0.00 +100.0% | $-0.37 +17.8% | $-0.45 +35.7% | $-0.70 +54.8% | $-1.55 | — |
| Total Assets | $383.5M +18.7% | $323.1M +0.1% | $322.6M -6.4% | $344.5M +13.2% | $304.4M +91.2% | $159.2M |
| Total Debt | $220.3M -10.9% | $247.2M +29.5% | $190.9M +2.1% | $187.1M +112.4% | $88.1M +1.2% | $87.0M |
| Operating Cash Flow | $28.6M +177.4% | $-37.0M +21.4% | $-47.0M +54.3% | $-102.9M -7.7% | $-95.5M -18.6% | $-80.6M |
| Free Cash Flow | — | — | — | — | $-96.6M -19.4% | $-80.9M |
Get alerted when XERS's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Xeris Biopharma Holdings, Inc. including:
Top Institutional Holders of XERS
BlackRock, Inc.
$115.0M14,525,539 shCAPSTONE INVESTMENT ADVISORS, LLC
$62.6M23,074,000 shD. E. Shaw & Co., Inc.
$61.8M7,804,758 shVANGUARD CAPITAL MANAGEMENT LLC
$58.1M7,340,229 shSTATE STREET CORP
$38.2M4,821,566 shGEODE CAPITAL MANAGEMENT, LLC
$37.4M4,718,183 shNuveen, LLC
$34.7M4,385,141 shPolar Asset Management Partners Inc.
$28.8M10,500,000 shRosalind Advisors, Inc.
$23.0M2,908,981 shQube Research & Technologies Ltd
$22.9M2,893,749 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $115.0M | 14,525,539 |
| CAPSTONE INVESTMENT ADVISORS, LLC | $62.6M | 23,074,000 |
| D. E. Shaw & Co., Inc. | $61.8M | 7,804,758 |
| VANGUARD CAPITAL MANAGEMENT LLC | $58.1M | 7,340,229 |
| STATE STREET CORP | $38.2M | 4,821,566 |
| GEODE CAPITAL MANAGEMENT, LLC | $37.4M | 4,718,183 |
| Nuveen, LLC | $34.7M | 4,385,141 |
| Polar Asset Management Partners Inc. | $28.8M | 10,500,000 |
| Rosalind Advisors, Inc. | $23.0M | 2,908,981 |
| Qube Research & Technologies Ltd | $22.9M | 2,893,749 |
Companies Similar to XERS
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Travere Therapeutics, Inc.
DELCATH SYSTEMS, INC.
Tarsus Pharmaceuticals, Inc.
SI-BONE, Inc.
Evolus, Inc.
ARDELYX, INC.
Verastem, Inc.
BIOCRYST PHARMACEUTICALS INC
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put XERS on your watchlist
Track score changes the day Xeris Biopharma Holdings, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is XERS a good stock to buy?
13F Pro's AI-powered analysis of Xeris Biopharma Holdings, Inc. (XERS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for XERS are available on the XERS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. XERS is classified as a small company.
Which hedge funds own XERS?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling XERS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Xeris Biopharma Holdings, Inc.'s investment landscape.